869682-23-5

Upstream product

• 186581-53-3 diazomethane 
• 67-56-1 methanol 
• 869681-94-7 (2S,4S)-4-(4-fluoro-phenoxy)-pyrrolidine-1,2-dicarboxylic acid-1-tert-butyl ester 
• 371-41-5 4-Fluorophenol 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 

Downstream Products

• 198968-99-9 (2S,4S)-4-(4-Fluoro-phenoxy)-pyrrolidine-2-carboxylic acid methyl ester 
• 869681-94-7 (2S,4S)-4-(4-fluoro-phenoxy)-pyrrolidine-1,2-dicarboxylic acid-1-tert-butyl ester 

Relevant academic research and scientific papers

Alkyl aryl ether bond formation with phenofluor

An alkyl aryl ether bond formation reaction between phenols and primary and secondary alcohols with PhenoFluor has been developed. The reaction features a broad substrate scope and tolerates many functional groups, and substrates that are challenging for more conventional ether bond forming processes may be coupled. A preliminary mechanistic study indicates reactivity distinct from conventional ether bond formation. From fluorination to etherification: A method for the formation of alkyl aryl ethers directly from the corresponding alcohols and phenols with PhenoFluor has been developed. The reaction features a broad substrate scope, and substrates that are challenging for more conventional ether bond forming processes may be coupled. TMS=trimethylsilyl.

PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS

This disclosure provides pharmaceutical compounds to treat medical disorders, such as complement-mediated disorders, including complement Cl -mediated disorders.

TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE

The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

IAP BIR domain binding compounds

A compound of Formula 1: (I) or salt thereof, as well as methods of making compounds of Formula 1, methods of using compounds of Formula 1 to treat proliferative disorders such as cancer, and related compounds, composition, and methods.